Arrhythmias & EP
From the Journals
Keeping thyroid hormone treatment on target is key for the heart
‘Both undertreatment and overtreatment were associated with adverse cardiovascular outcomes,’ including higher mortality, but keeping thyroid...
Commentary
Taking cardiac pacing from boring to super cool
Ablation has hogged the electrophysiology spotlight recently, but three presentations at the 2022 Heart Rhythm Society meeting put cardiac pacing...
From the Journals
Antithrombotic therapies shifting for Watchman LAA occlusion
National registry data show substantial deviation from the treatment protocols used in the pivotal randomized trials in the years following...
Conference Coverage
Cutting dementia risk in AFib: Does rhythm control strategy matter?
The way sinus rhythm is restored in patients with atrial fibrillation might make a difference to risk for later dementia.
Conference Coverage
Cutting dementia risk in atrial fibrillation: Does rhythm control strategy matter?
Feature
Will you have cardiac arrest? New tech may predict if and when
Researchers at Johns Hopkins University want to create a 3D model of your heart to predict a life-threatening problem before it happens.
From the Journals
Study points to causal role for Lp(a) in atrial fibrillation
The relation is relatively modest but strongly argues for increased testing of Lp(a) and adding atrial fibrillation as a secondary outcome to...
Conference Coverage
Young and older athletes show similar arrhythmia patterns with fQRS
Some structural changes were observed, but had no impact on exercise-induced arrhythmias in adolescent athletes.
Conference Coverage
New smart device shows highly accurate AFib detection: mAFA II
The study, conducted in a mass low-risk population in China, correctly identified atrial fibrillation in more than 93% of suspected cases detected...
Latest News
COVID-19 cardiovascular complications in children: AHA statement
The statement details what has been learned about how to treat, manage, and prevent cardiovascular complications associated with COVID-19 in...
Conference Coverage
Empagliflozin rapidly improves acute heart failure symptoms in hospitalized patients
Empagliflozin showed symptomatic benefits in patients hospitalized for acute heart failure after 2 weeks in a secondary analysis from the EMPULSE...